Pioneering Breakthrough in Diabetes Treatment: Hua Medicine's HuaTangNing Soars

Dr. Li Chen, CEO of Hua Medicine, won the C.C. Tan Life Science Industrialization Award for his significant contributions to the biopharmaceutical industry in China. His company developed HuaTangNing, the world's first Glucokinase Activator drug for diabetes, achieving global recognition and addressing critical unmet clinical needs.

In a groundbreaking achievement, Dr. Li Chen, CEO of Hua Medicine, was honored with the prestigious C.C. Tan Life Science Industrialization Award. The ceremony, deemed the pinnacle of life sciences recognition in China, took place in Shenyang on October 9th. This accolade is a testament to Dr. Chen’s exceptional contributions to the industrialization of life sciences in the country.

Dr. Chen, a pivotal figure in the Chinese biopharmaceutical landscape, returned to Shanghai in 2004 to spearhead innovation. From founding Roche China's R&D center to launching Hua Medicine, his journey reflects a commitment to transforming unmet clinical needs in diabetes treatment into actionable breakthroughs. Hua Medicine's flagship, HuaTangNing, a trailblazing Glucokinase Activator, gained approval as a first-in-class treatment, unlocking new avenues in managing chronic diseases.

The success journey of HuaTangNing marks a significant stride in drug development, resonating as the first globally approved Glucokinase Activator derived from nearly a decade of rigorous research. Collaborating with Bayer Healthcare, HuaTangNing has surpassed revenue thresholds and is now listed in China’s National Reimbursement Drug List, shaping the future of diabetes management. Dr. Chen's leadership has solidified his influence in both scientific research and sector-wide advancements in China's biopharmaceutical ecosystem.

(With inputs from agencies.)